The most recent clinical study on JAK inhibitors in breast cancer was reported in 2021 on trastuzumab-resistant HER2-positive breast cancer patients, and the addition of ruxolitinib to trastuzumab did not improve the treatment outcome in these patients [146]. Here, ERBB2 is linked to breast cancer.